These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.
143 related articles for article (PubMed ID: 35242564)
1. Use of tafenoquine to treat a patient with relapsing babesiosis with clinical and molecular evidence of resistance to azithromycin and atovaquone. Marcos LA; Leung A; Kirkman L; Wormser GP IDCases; 2022; 27():e01460. PubMed ID: 35242564 [TBL] [Abstract][Full Text] [Related]
2. Tafenoquine for Relapsing Babesiosis: A Case Series. Krause PJ; Rogers R; Shah MK; Kang H; Parsonnet J; Kodama R; Vannier E Clin Infect Dis; 2024 Jul; 79(1):130-137. PubMed ID: 38814096 [TBL] [Abstract][Full Text] [Related]
3. Broad Antimicrobial Resistance in a Case of Relapsing Babesiosis Successfully Treated With Tafenoquine. Rogers R; Krause PJ; Norris AM; Ting MH; Nagami EH; Cilley B; Vannier E Clin Infect Dis; 2023 Feb; 76(4):741-744. PubMed ID: 35684960 [TBL] [Abstract][Full Text] [Related]
4. Emergence of resistance to azithromycin-atovaquone in immunocompromised patients with Babesia microti infection. Wormser GP; Prasad A; Neuhaus E; Joshi S; Nowakowski J; Nelson J; Mittleman A; Aguero-Rosenfeld M; Topal J; Krause PJ Clin Infect Dis; 2010 Feb; 50(3):381-6. PubMed ID: 20047477 [TBL] [Abstract][Full Text] [Related]
5. Tafenoquine-Atovaquone Combination Achieves Radical Cure and Confers Sterile Immunity in Experimental Models of Human Babesiosis. Vydyam P; Pal AC; Renard I; Chand M; Kumari V; Gennaro JC; Mamoun CB J Infect Dis; 2024 Jan; 229(1):161-172. PubMed ID: 38169301 [TBL] [Abstract][Full Text] [Related]
6. Combination of Clofazimine and Atovaquone as a Potent Therapeutic Regimen for the Radical Cure of Babesia microti Infection in Immunocompromised Hosts. Tuvshintulga B; Sivakumar T; Nugraha AB; Ahedor B; Batmagnai E; Otgonsuren D; Liu M; Xuan X; Igarashi I; Yokoyama N J Infect Dis; 2022 Jan; 225(2):238-242. PubMed ID: 34664651 [TBL] [Abstract][Full Text] [Related]
7. Clinical and Molecular Evidence of Atovaquone and Azithromycin Resistance in Relapsed Babesia microti Infection Associated With Rituximab and Chronic Lymphocytic Leukemia. Simon MS; Westblade LF; Dziedziech A; Visone JE; Furman RR; Jenkins SG; Schuetz AN; Kirkman LA Clin Infect Dis; 2017 Oct; 65(7):1222-1225. PubMed ID: 28541469 [TBL] [Abstract][Full Text] [Related]
8. Atovaquone in the treatment of Babesia microti infections in hamsters. Wittner M; Lederman J; Tanowitz HB; Rosenbaum GS; Weiss LM Am J Trop Med Hyg; 1996 Aug; 55(2):219-22. PubMed ID: 8780464 [TBL] [Abstract][Full Text] [Related]
9. Clofazimine, a Promising Drug for the Treatment of Babesia microti Infection in Severely Immunocompromised Hosts. Tuvshintulga B; Vannier E; Tayebwa DS; Gantuya S; Sivakumar T; Guswanto A; Krause PJ; Yokoyama N; Igarashi I J Infect Dis; 2020 Aug; 222(6):1027-1036. PubMed ID: 32310272 [TBL] [Abstract][Full Text] [Related]
10. Failure of an Approximately Six Week Course of Tafenoquine to Completely Eradicate Prasad PJ; Wormser GP Pathogens; 2022 Sep; 11(9):. PubMed ID: 36145484 [TBL] [Abstract][Full Text] [Related]
11. Activities of artesunate-based combinations and tafenoquine against Babesia bovis in vitro and Babesia microti in vivo. Carvalho LJM; Tuvshintulga B; Nugraha AB; Sivakumar T; Yokoyama N Parasit Vectors; 2020 Jul; 13(1):362. PubMed ID: 32690081 [TBL] [Abstract][Full Text] [Related]
12. Relapsing Babesiosis With Molecular Evidence of Resistance to Certain Antimicrobials Commonly Used to Treat Marcos LA; Wormser GP Open Forum Infect Dis; 2023 Aug; 10(8):ofad391. PubMed ID: 37539067 [TBL] [Abstract][Full Text] [Related]
13. Plasma Blood Levels of Tafenoquine following a Single Oral Dosage in BALBc Mice with Acute Mordue DG; Hale SJ; Dennis WE; Vuong CV; Li XM; Yang N; Wormser GP Pathogens; 2023 Aug; 12(9):. PubMed ID: 37764921 [TBL] [Abstract][Full Text] [Related]
14. Could the Drug Tafenoquine Revolutionize Treatment of Babesia microti Infection? Mordue DG; Wormser GP J Infect Dis; 2019 Jul; 220(3):442-447. PubMed ID: 31099380 [TBL] [Abstract][Full Text] [Related]
15. Efficacy, safety and tolerance of imidocarb dipropionate versus atovaquone or buparvaquone plus azithromycin used to treat sick dogs naturally infected with the Babesia microti-like piroplasm. Checa R; Montoya A; Ortega N; González-Fraga JL; Bartolomé A; Gálvez R; Marino V; Miró G Parasit Vectors; 2017 Mar; 10(1):145. PubMed ID: 28292316 [TBL] [Abstract][Full Text] [Related]
16. Holbrook NR; Klontz EH; Adams GC; Schnittman SR; Issa NC; Bond SA; Branda JA; Lemieux JE Open Forum Infect Dis; 2023 Mar; 10(3):ofad097. PubMed ID: 36968958 [TBL] [Abstract][Full Text] [Related]
17. Treatment of refractory Babesia microti infection with atovaquone-proguanil in an HIV-infected patient: case report. Vyas JM; Telford SR; Robbins GK Clin Infect Dis; 2007 Dec; 45(12):1588-90. PubMed ID: 18190320 [TBL] [Abstract][Full Text] [Related]
18. Atovaquone and azithromycin for the treatment of babesiosis. Krause PJ; Lepore T; Sikand VK; Gadbaw J; Burke G; Telford SR; Brassard P; Pearl D; Azlanzadeh J; Christianson D; McGrath D; Spielman A N Engl J Med; 2000 Nov; 343(20):1454-8. PubMed ID: 11078770 [TBL] [Abstract][Full Text] [Related]